We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Tribal Sports Nutrition

Status: Active

Dec 7th 2020 - Jan 6th 2021

Tribal Sports Nutrition (TSN) uses the revitalising properties of the Baobab fruit to create energy smoothies. TSN claims that its smoothies are less concentrated than other sports nutrition brands, are 100% organic, and easy on the stomach. The company also incorporates vitamin C, antioxidants, fibre, and electrolytes into the smoothies to make it the on-the-go snack for active lifestyle consumers. TSN asserts that its baobab ingredient is wild-harvested by cooperatives in Africa, bringing income to people and preserving the local ecology. The company received a certification from the Organic Food Federation (OFF) and aims to achieve B Corp status. TSN's products have been listed in Sainsbury's and on Amazon. It will use the investment to double its existing product offering in 2021 and launch hydration, plant protein recovery products, and Baobab energy snacks.

read more read less

Tribal Sports Nutrition Rating Review

Pitch rating powered by CROWDRATING

Rated on 21/12/2020

Pitch Rated

86%

Gold

Management

87%

Product

81%

Investment

91%

Log in to view amount pledged

    Log in to view target

    £1,099,771
    pre-money valuation

    18.52%
    equity available

    259
    investors

    £1,628
    pledge per investor

    08249901
    company number

    Active
    company status

    11/10/2012
    incorporated 12 years

    £0.75
    share price

    Officers

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 82%
The management team at Tribal Sports Nutrition includes skilled professionals with expertise in management, technology, finance and marketing. It consists of an experienced Founder/CEO, Marketing/Investor Relations head, Commercial/Trading Head, and Product Development Head. The Chairman/CEO is a senior executive with expertise in Strategic Planning, Start-Up, and Project Management. He also has prior experience of working at the same stage of business growth. The Product Development Head specialises in New Business Development and Sales Management. Their Commercial/Trading Head has skills to build the brand and increase brand awareness through Marketing Strategy, Sales Management, Fast-Moving Consumer Goods (FMCG), and Key Account Management. The Marketing/Investor Relations Head handles the company's finances.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £1,099,771
    pre-money valuation

    18.52%
    equity available

    259
    investors

    £1,628
    pledge per investor

    08249901
    company number

    Active
    company status

    11/10/2012
    incorporated 12 years

    £0.75
    share price

    Officers
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph